SLN vs. MREO, BNTC, AURA, CYRX, RNAC, TSVT, AQST, TSHA, ATXS, and ATYR
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), Aura Biosciences (AURA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry.
Silence Therapeutics vs.
Mereo BioPharma Group (NASDAQ:MREO) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Mereo BioPharma Group currently has a consensus target price of $7.71, suggesting a potential upside of 285.71%. Silence Therapeutics has a consensus target price of $40.67, suggesting a potential upside of 1,352.38%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Mereo BioPharma Group.
Mereo BioPharma Group received 10 more outperform votes than Silence Therapeutics when rated by MarketBeat users. Likewise, 80.30% of users gave Mereo BioPharma Group an outperform vote while only 79.63% of users gave Silence Therapeutics an outperform vote.
Mereo BioPharma Group has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Mereo BioPharma Group's return on equity of 0.00% beat Silence Therapeutics' return on equity.
In the previous week, Mereo BioPharma Group had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Mereo BioPharma Group and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.89 beat Mereo BioPharma Group's score of 0.63 indicating that Silence Therapeutics is being referred to more favorably in the news media.
62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Mereo BioPharma Group has higher earnings, but lower revenue than Silence Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mereo BioPharma Group has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Summary
Mereo BioPharma Group beats Silence Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLN) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy SLN Stock Free SLN Stock Alerts